TY - JOUR
T1 - Polysaccharide-containing conjugate vaccines for fungal diseases
AU - Casadevall, Arturo
AU - Pirofski, Liise Anne
PY - 2006/1
Y1 - 2006/1
N2 - The recognition that antibodies are effective against fungal pathogens has spawned interest in developing vaccines that elicit antibody-mediated protection. Recently, a novel polysaccharide-protein conjugate vaccine that uses the algal antigen laminarin was shown to elicit antibodies to β-glucan in fungal cell walls and to mediate protection against both experimental candidiasis and aspergillosis. Remarkably, vaccine-induced antibodies manifested direct antifungal effects, suggesting that vaccine efficacy might not require cellular or other components of the immune system. The description of a vaccine that could protect against various fungal pathogens opens exciting new dimensions in the search for approaches to control fungal diseases.
AB - The recognition that antibodies are effective against fungal pathogens has spawned interest in developing vaccines that elicit antibody-mediated protection. Recently, a novel polysaccharide-protein conjugate vaccine that uses the algal antigen laminarin was shown to elicit antibodies to β-glucan in fungal cell walls and to mediate protection against both experimental candidiasis and aspergillosis. Remarkably, vaccine-induced antibodies manifested direct antifungal effects, suggesting that vaccine efficacy might not require cellular or other components of the immune system. The description of a vaccine that could protect against various fungal pathogens opens exciting new dimensions in the search for approaches to control fungal diseases.
UR - http://www.scopus.com/inward/record.url?scp=30644466326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=30644466326&partnerID=8YFLogxK
U2 - 10.1016/j.molmed.2005.11.003
DO - 10.1016/j.molmed.2005.11.003
M3 - Short survey
C2 - 16309965
AN - SCOPUS:30644466326
SN - 1471-4914
VL - 12
SP - 6
EP - 9
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 1
ER -